The FDA’s advisory committees delivered notable decisions impacting drug approvals. The Psychopharmacologic Drugs Advisory Committee voted 10-1 against approving Otsuka’s Rexulti combined with Zoloft for PTSD treatment, citing failed phase 3 trials and overlapping components. Meanwhile, an Oncologic Drugs Advisory Committee voted against the approval of GSK's Blenrep antibody-drug conjugate for multiple myeloma in two combination regimens, due to concerns over ocular toxicity, dosage optimization, and patient demographics in pivotal trials. These actions underscore ongoing regulatory scrutiny over safety and efficacy in psychiatric and cancer therapies.